REC 0438

Drug Profile

REC 0438

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Recordati
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Overactive bladder

Most Recent Events

  • 25 Apr 2016 Phase-I/II clinical trials in Overactive bladder in European Union (Intravesicular) before April 2016
  • 20 Mar 2016 Phase-I development is ongoing in Italy
  • 31 Dec 2011 Phase-I clinical trials in Overactive bladder in Italy (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top